Kythera submits ATX-101 NDA for submental fat

Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) submitted an NDA to FDA for deoxycholic acid (ATX-101) to reduce submental (under chin) fat. Kythera plans to submit multiple ex-U.S. regulatory submissions by 2Q15. In March, Kythera reacquired U.S. and Canada rights to the synthetic sodium deoxycholate from Bayer AG (Xetra:BAYN) (see BioCentury Extra, March 10). ...